Navigation Links
National Cancer Institute: Battling Cancer and a Recession

DURHAM, N.C., Jan. 16 /PRNewswire-USNewswire/ -- Despite difficult financial times and flat federal funding of biomedical research, five important actions -- which can be implemented rapidly and at modest cost -- can yield dramatic results for patients and the public. So write three leaders of the National Cancer Institute (NCI) in a commentary published today by "The Oncologist."

(Logo: )

In the article, James H. Doroshow, M.D., director of NCI's Division of Cancer Treatment and Diagnosis; Robert T. Croyle, Ph.D., director of its Division of Cancer Control and Population Sciences; and John E. Niederhuber, M.D., director of the National Cancer Institute recommend:

-- Significantly increasing enrollment of Medicare patients into cancer clinical trials, by modestly increasing the Medicare reimbursement rate for the type of office visits required for patients entered into clinical trials.

-- Increasing collaborations between NCI and the Centers for Medicare and Medicaid Services to determine the effectiveness of new cancer drugs.

-- Undertaking a national outcomes research demonstration project, to help close the gap between the rapid pace of innovation in biomedicine and our ability to harness it to improve population health.

-- Leveraging existing tobacco-control collaborations and possible new authorities at the U.S. Food and Drug Administration, tackle tobacco control with the seriousness and energy it deserves.

-- Disseminating information about and implementing greater levels of colorectal cancer screening.

This short list of actions, the authors propose, "has the potential for substantial clinical and public health impact at minimal cost. All of these can be implemented quickly because they build directly on existing research, clinical, and public health models." Taken together, the total cost of these five initiatives would be $210 million.

Bruce A. Chabner, M.D., editor-in-chief of "The Oncologist" in a lead editorial summarized that, "as a nation, we must proceed with the conquest of this disease, despite our economic limitations. The scientific opportunities have never been greater and, as our population ages and other diseases come under control, cancer will play an increasingly dominant place in America's health ... and health policy." "On the eve of the inauguration of President-elect Obama," Dr. Chabner continued, "there is enormous opportunity, and medical research is perhaps the area in which our country has its greatest leadership role and its greatest potential for economic return on its investment."

Both papers published by "The Oncologist," are freely available: Chabner Editorial:

    NCI Commentary:

About AlphaMed Press

AlphaMed Press publishes the internationally renowned journals, "Stem Cells" and "The Oncologist." "Stem Cells," now in its 27th year, is the oldest and one of the world's top-tier peer-reviewed monthly journals in the fast-paced area of stem cells and regenerative medicine. "The Oncologist," in its 14th year, is a premier peer-reviewed monthly journal dedicated to physicians entrusted with the care of cancer patients. View AlphaMed Press journals at


Dr. Martin J. Murphy, Executive Editor: 919.641.5304;

Dr. Bruce A. Chabner, Editor-in-Chief: 617-724-3136;

SOURCE AlphaMed Press
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
6. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
7. Arrow International Files and Mails Definitive Proxy Materials
8. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
9. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
10. Viragen International to Reverse Split Its Common Stock
11. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
Post Your Comments:
(Date:11/27/2015)... , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc ... announced today that it has closed the sale of ... to Guerbet (GBT- NYSE Euronext) in a transaction valued ... four manufacturing facilities and a total of approximately 1,000 ... the St. Louis area. This ...
(Date:11/26/2015)... 26, 2015 ... Accutest Research Laboratories, a leading independent ... (CRO), has formed a strategic partnership ... Temple Health for joint work on ... ) , --> ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
Breaking Biology Technology:
(Date:11/18/2015)... --> --> ... report titled  Gesture Recognition Market - Global Industry Analysis, ... to the report, the global gesture recognition market was valued at ... US$29.1 bn by 2021, at a CAGR of 20.3% ... dominated the global gesture recognition market in ...
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
Breaking Biology News(10 mins):